Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-002 Trial
TOKYO and RAHWAY, N.J., A […]
ป้ายกำกับ: patients
Lemon Healthcare Uses Blockchain Technology to Improve the Smart Healthcare Ecosystem for Patients
Seoul, Korea,June8, 2022- […]
Hua Medicine Announces Dorzagliatin can Restore Glucose Sensitivity and Early Phase Insulin Secretion in T2DM and GCK-MODY Patients at ADA 2022
SHANGHAI, CHINA, Jun 7, 2 […]
Eisai Presents New Findings for Antibody Drug Conjugate Farletuzumab Ecteribulin at 2022 ASCO Annual Meeting
TOKYO, Jun 6, 2022 – […]
Eisai Contributes to the Science of Cancer Medicine at ASCO 2022
TOKYO, May 27, 2022 ̵ […]
Eisai: Announcement About an Approval for Additional Indication of Jyseleca, JAK inhibitor
TOKYO, Mar 28, 2022 ̵ […]
Innovative AI Technology Aids Personalized Care for Diabetes Patients Needing Complex Drug Treatment
Tokyo and Salt Lake City, […]
IND Application for SinoMab’s First-in-Class Asthma Therapeutic Product SM17 Approved by FDA
HONG KONG, Mar 14, 2022 & […]
LENVIMA in Combination with KEYTRUDA Approved In Taiwan for the Treatment of Patients with Advanced Endometrial Carcinoma
TOKYO, Mar 7, 2022 – […]
Eisai: LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Approved in Japan for Radically Unresectable or Metastatic Renal Cell Carcinoma
TOKYO and KENILWORTH, N.J […]
Eisai to Present Abstracts on Lenvatinib at 2022 ASCO Gastrointestinal Cancers Symposium
TOKYO, Jan 17, 2022 ̵ […]
Biogen Announces Reduced Price for Aduhelm to Improve Access For Patients With Early Alzheimer’s Disease In The United States
TOKYO, Dec 21, 2021 ̵ […]
Eisai to Present Latest Data on Perampanel and E2730 at the 75th American Epilepsy Society Annual Meeting
TOKYO, Nov 30, 2021 ̵ […]
Transgene and NEC Announce Positive Preliminary Data from Phase I Studies of TG4050, a Novel Individualized Neoantigen Cancer Vaccine
Strasbourg, France & […]
Edison Oncology and Apollomics Announce Treatment of First Patient with EO1001 (APL-122) in a Phase I/IIa Clinical Trial
MENLO PARK, CA and HELSIN […]
Eisai: Fully Human Anti-TNFalpha Monoclonal Antibody HUMIRA Obtains Additional Approval
TOKYO, Sep 27, 2021 ̵ […]
Researchers Present Key Research Results on Diabetes Remission of Dorzagliatin
SHANGHAI, Sep 26, 2021 &# […]
Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO Virtual Congress 2021
TOKYO, Sep 14, 2021 ̵ […]
Adlai Nortye Announces First Patient Dosed in Phase Ia Clinical Trial of AN2025 and AN0025 in Combination with atezolizumab for Advanced Solid Tumors
NEW JERSEY, the U.S. and […]
Eisai’s Anti-Epileptic Drug Fycompa Approved In China As Monotherapy For Partial-Onset Seizures And Pediatric Indication For Partial-Onset Seizures
TOKYO, Aug 2, 2021 – […]
Eisai: FDA Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination for Patients With Certain Types of Advanced Endometrial Carcinoma
TOKYO and KENILWORTH, N.J […]
Eisai Launchs Bile Acid Transporter Inhibitor Goofice in Thailand
TOKYO, Jul 19, 2021 ̵ […]
Biogen and Eisai launch initiatives to help patients with Alzheimer’s disease access ADUHELM
Cambridge, MA, Jun 8, 202 […]
FDA grants accelerated approval for ADUHELM as the first and only Alzheimer’s disease treatment to address a defining pathology of the disease
TOKYO, Jun 8, 2021 – […]
Eisai to Present Data on Oncology Pipeline and Products at ASCO Annual Meeting
TOKYO, May 20, 2021 ̵ […]
Anticancer Agent “Remitoro Intravenous Drip Infusion 300 microgram” (Denileukin Diftitox (Genetical Recombination)) Launched in Japan
Tokyo, May 19, 2021 ̵ […]
Hua Medicine Announces Acceptance of a New Drug Application for Dorzagliatin in China – First Glucokinase Activator (GKA) Globally
SHANGHAI, CHINA, Apr 23, […]
